Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain
González Juanatey, Carlos; Anguita-Sánchez, M.; Barrios, V.; Núñez-Gil, I.; Gómez-Doblas, J.J.; García-Moll, X.; Lafuente-Gormaz, C.; Rollán-Gómez, M.J.; Peral-Disdier, V.; Martínez-Dolz, L.; Rodríguez-Santamarta, M.; Viñolas-Prat, X.; Soriano-Colomé, T.; Muñoz-Aguilera, R.; Plaza, I.; Curcio-Ruigómez, A.; Orts-Soler, E.; Segovia-Cubero, J.; Fanjul, V.; Marín-Corral, J.; Cequier, Á.

Identificadores
Identificadores
Visualización o descarga de ficheros
Visualización o descarga de ficheros
Fecha de publicación
2023Título de revista
Journal of Clinical Medicine
Tipo de contenido
Artigo
Resumen
Patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) without myocardial infarction (MI) or stroke are at high risk for major cardiovascular events (MACEs). We aimed to provide real-world data on age-related clinical characteristics, treatment management, and incidence of major cardiovascular outcomes in T2DM-CAD patients in Spain from 2014 to 2018. We used EHRead® technology, which is based on natural language processing and machine learning, to extract unstructured clinical information from electronic health records (EHRs) from 12 hospitals. Of the 4072 included patients, 30.9% were younger than 65 years (66.3% male), 34.2% were aged 65-75 years (66.4% male), and 34.8% were older than 75 years (54.3% male). These older patients were more likely to have hypertension (OR 2.85), angina (OR 1.64), heart valve disease (OR 2.13), or peripheral vascular disease (OR 2.38) than those aged <65 years (p < 0.001 for all comparisons). In general, they were also more likely to receive pharmacological and interventional treatments. Moreover, these patients had a significantly higher risk of MACEs (HR 1.29; p = 0.003) and ischemic stroke (HR 2.39; p < 0.001). In summary, patients with T2DM-CAD in routine clinical practice tend to be older, have more comorbidities, are more heavily treated, and have a higher risk of developing MACE than is commonly assumed from clinical trial data.
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)
